Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of Gram-positive cocci

International Journal of Antimicrobial Agents

Volumn 32, Issue SUPPL. 3, 2008, Pages

  Tsao, Shih Ming ^a   Lin, Hsiu Chen ^b   Lee, Chun Ming ^c   Hsu, Gwo Jong ^d   Chen, Chih Ming ^e   Sun, Wu ^f   Liu, Yung Ching ^g   Jang, Tsrang Neng ^h   Cheng, Yu Jen ⁱ   Lu, Po Liang ^j   Chiang, Ping Chreng ^k   Wang, Lih Shinn ^l   Kung, Hsiang Chi ^m   Chuang, Yin Ching ⁿ   Shi, Zhi Yuan ^o   Liu, Jien Wei ^p   Huang, Cheng Hua ^q   Lu, Chin Te ^r   Liao, Chun Hsing ^s   Hsueh, Po Ren ^m  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^e TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^f Pao Chien Hospital   (Taiwan)

^g KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^h SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

ⁱ CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^j KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^k CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^l BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^m NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

ⁿ CHI MEI MEDICAL CENTER   (Taiwan)

^o TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^p CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^q CATHAY GENERAL HOSPITAL   (Taiwan)

^r LOTUNG POH AI HOSPITAL   (Taiwan)

^s FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

more..

Author keywords

Broth microdilution; Etest; Gram positive cocci; Taiwan; Tigecycline

Indexed keywords

TIGECYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; DRUG SURVEILLANCE PROGRAM; ENTEROCOCCUS FAECIUM; EPSILOMETER TEST; FOOD AND DRUG ADMINISTRATION; GRAM POSITIVE COCCI; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; TAIWAN; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; TAIWAN;

EID: 55649083497     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(08)70025-6     Document Type: Article

References (21)

1. Pfaller M.A., Jones R.N., Doern G.V., Sader H.S., Kugler K.C., and Beach M.L. Survey of blood stream infections attributable to gram positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 33 (1999) 283-297
2. Tenover F.C. Implications of vancomycin-resistant Staphylococcus aureus. J Hosp Infect 43 (1999) S3-S7
3. Srinivasan A., Dick J.D., and Perl T.M. Vancomycin resistance in staphylococci. Clin Microbiol Rev 15 (2002) 430-438
4. Hsueh P.R., Chen W.H., Teng L.J., and Luh K.T. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents 26 (2005) 43-49 Erratum: Int J Antimicrob Agents 2006;27:576.
5. Huang Y.T., Liao C.H., Teng L.J., and Hsueh P.R. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan. Clin Microbiol Infect 14 (2008) 124-129
6. Pankey G.A. Tigecycline. J Antimicrob Chemother 56 (2005) 470-480
7. Bouchillon S.K., Hoban D.J., Johnson B.M., Johnson J.L., Hsiung A., Dowzicky M.J., and Tigecycline Evaluation and Surveillance Trial (TEST) Group. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 52 (2005) 173-179
8. Roveta S., Marchese A., and Debbia E.A. Tigecycline in vitro activity against gram- negative and gram-positive pathogens collected in Italy. Chemotherapy 54 (2008) 43-49
9. Clinical and Laboratory Standards Institute. Methods for dilution antimi- crobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A7. 7th ed. (2006), Clinical and Laboratory Standards Institute, Wayne, PA
10. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: M100-S16, 16th informational supplement (2006), Clinical and Laboratory Standards Institute, Wayne, PA
11. Food and Drug Administration. Class II special controls guidance document: antimicrobial susceptibility test systems (AST); guidance for industry (2007), US Department of Health and Human Services, Food and Drug Administration, Washington, DC. http://www.fda.gov/cdrh/oivd/guidance/631.pdf [accessed 13 October 2008].
12. National Committee for Clinical Laboratory Standards. Development of in vitro susceptibility testing criteria and quality control parameters: approved standard M23-A2 (2000), National Committee for Clinical Laboratory Standards, Wayne, PA
13. Kronvall G., Karlsson I., Walder M., Sörberg M., and Nilsson L.E. Epidemiological MIC cut-off values for tigecycline calculated from Etest values using normalized resistance interpretation. J Antimicrob Chemother 57 (2006) 498-505
14. Hope R., Parsons T., Mushtaq S., James D., and Livermore D.M. Determination of disc breakpoints and evaluation of Etest for tigecycline susceptibility testing by the BSAC method. J Antimicrob Chemother 60 (2007) 770-774
15. Citron D.M., Ostovari M.I., Karlsson, and Goldstein E.C. Evaluation of the Etest for susceptibility test of anaerobic bacteria. J Clin Microbiol 29 (1991) 2197-2203
16. Rosenblatt J.E., and Gustafson D.R. Evaluation of E-test for susceptibility testing of anaerobic bacteria. Diagn Microbiol Infect Dis 22 (1995) 279-284
17. Zhang Y.Y., Zhou L., Zhu D.M., Wu P.C., Hu F.P., Wu W.H., et al. In vitro activities of tigecycline against clinical isolates from Shanghai, China. Diagn Microbiol Infect Dis 50 (2004) 267-281
18. Bantar C., Schell C., Posse G., Limansky A., Ballerini V., and Mobilia L. Comparative time-kill study of doxycycline, tigecycline, sulbactam, and imipenem against several clones of Acinetobacter baumannii. Diagn Microbiol Infect Dis 61 (2008) 309-314
19. LaPlante K.L., Rybak M.J., Leuthner K.D., and Chin J.N. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model. Antimicrob Agents Chemother 50 (2006) 1298-1303
20. Vouillamoz J., Moreillon P., Giddey M., and Entenza J.M. In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens. J Antimicrob Chemother 61 (2008) 371-374
21. Carroll K.C., Cohen S., Nelson R., Campbell D.M., Claridge J.D., Garrison M.W., et al. Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 32 (1998) 229-235